| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 872 | 555 | 33 |
| Full Text Views | 13 | 1 | 0 |
| PDF Downloads | 12 | 0 | 0 |
Field Evaluation of Primaquine in the Control of Plasmodium Vivax
Rafael A. Cedillos
Rafael A. Cedillos
Central America Research Station, Bureau of Tropical Diseases, Center for Disease Control, Public Health Service, United States Department of Health, Education, and Welfare, San Salvador, El Salvador, C.A.
Search for other papers by Rafael A. Cedillos in
Current site
Google Scholar
PubMed
Search for other papers by Rafael A. Cedillos in
Current site
Google Scholar
PubMed
McWilson Warren
McWilson Warren
Central America Research Station, Bureau of Tropical Diseases, Center for Disease Control, Public Health Service, United States Department of Health, Education, and Welfare, San Salvador, El Salvador, C.A.
Search for other papers by McWilson Warren in
Current site
Google Scholar
PubMed
Search for other papers by McWilson Warren in
Current site
Google Scholar
PubMed
Geoffrey M. Jeffery
Geoffrey M. Jeffery
Central America Research Station, Bureau of Tropical Diseases, Center for Disease Control, Public Health Service, United States Department of Health, Education, and Welfare, San Salvador, El Salvador, C.A.
Search for other papers by Geoffrey M. Jeffery in
Current site
Google Scholar
PubMed
Search for other papers by Geoffrey M. Jeffery in
Current site
Google Scholar
PubMed
Two regimens of primaquine in combination with amodiaquine have been compared with amodiaquine alone in known cases of Plasmodium vivax in an endemic area of El Salvador, C.A. A 5-day regimen of primaquine, with dosages based on an adult dose of 15 mg per day, produced a substantial reduction in the numbers of patients experiencing renewed parasite activity and in the number of parasitemias experienced by the group during 9 mo of posttreatment observation, when compared with patients treated only with amodiaquine. A single dose regimen, based on an adult dose of 45 mg, similarly reduced the number of patients with renewed parasite activity and the number of parasitemias in the group. Those patients who experienced malaria attacks subsequent to treatment with either primaquine regimen experienced fewer such attacks than did those receiving amodiaquine alone. It is concluded that such primaquine regimens, which are more practicable for field use than the full 14-day curative regimen, are of value to both the patient and the community through the reduction of parasite episodes and the reduction of the source of mosquito infection for continuation of transmission.
Author Notes
Present address: WHO-Chagas' Disease Vector Research Unit, Maracay, Venezuela.
Present address: Bureau of Tropical Diseases, Center for Disease Control, 1600 Clifton Road, Atlanta, Georgia 30333.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 872 | 555 | 33 |
| Full Text Views | 13 | 1 | 0 |
| PDF Downloads | 12 | 0 | 0 |